• broken image

    From mRNA to Cure

    By analyzing RNA we can detect disease, monitor health, and design Next Generation Cures


    Our OneRNA platform enables repurposing of existing drugs on an individual patient basis and the development of individualized novel RNA therapeutics e.g. RNA vaccines to develop Next Generation Cures.

    broken image


    Looking for better treatment options for your patients? Our OneRNA Platform enables repurposing existing drugs on an individual patient basis

    broken image


    Using just one biomarker can save $1B during clinical development.

    The OneRNA Platform makes the companion diagnostic into an algorithm and rapidly translates RNA code to novel RNA Theraputics

  • RNA Platform

    By analyzing RNA we can monitor health, detect disease and design next generation cures

    DNA is not your fate. RNA is coding for proteins and proteins are targets for drugs, today RNA is directly a target for drugs and a drug itself. We are experts in analyzing RNA using Next Generation Sequencing and translating RNA Code to RNA Therapeutics to individualize treatment

    broken image

    OneRNA® for treatment selection in cancer

    DNA is not your fate. RNA codes for proteins and proteins are targets for drugs, furthermore today RNA is directly a target for drugs and a drug itself. We coded all that information into our OneRNA® platform and initiated 3 clinical studies to produce supporting data.

  • OneRNA4Bladder

    Genomic Expression is starting a large study testing OneRNA together with selected DNA markers as a liquid biopsy platformBladder cancer is the most expensive cancer to treatDue to very invasive and expensive diagnostic procedures and a high recurrence rate



    Substituting the use of cystoscopy for the detection of bladder cancer



    Treat based on OneRNA rather than standard of care



    Monitor effectiveness of treatment in simple urine test



    Optimize treatment real time to prevent recurrence and ineffective treatments


    Experienced Management Team with Startup RNA

    broken image

    Gitte Pedersen

    CEO and co-founder

    Gitte Pedersen, CEO is a former executive at NovoZymes, the world’s largest enzyme manufacturer. She has advised the Danish Government and early stage biotech companies regarding their corporate development in the US


    Follow at DNABARCODE

    broken image

    Morten Pedersen

    CSO and cofounder

    Morten Pedersen, CTO and co-founder holds a Ph.D in genomics. He has a very strong innovation track record with multiple key patents in genomics. Morten is the inventor of Genomic Expression’s sample prep technologies

    broken image

    Jesper Zeuthen

    VP Oncology research

    Jesper Zeuthen, CMO, is the co-founder of GeneMap and Topotarget (both had IPOs), and prior to that he established one of the laboratories that became the Danish Cancer Society.

  • Buy OneRNA(TM)

    Send us your samples or your RNA-seq data and we will send you an actionable report back

  • What our Customers say

    We work with corporations and governments to enable safe reopening our economy

    broken image

    Laura Dinsmore, President and CEO

    Quadrant Health Strategies, Inc.

    "We highly value our collaboration with Genomic Expression. We have worked with them since they launched COVID19 testing and have been impressed with their turnaround time and extraordinary customer service, consistently stepping up, often on short notice"


    broken image

    Mike Horrocks, CEO

    EREMA North America, Inc.

    " Access to rapid and accurate COVID19 testing for our employees is critical in allowing us to keep our facility open and to support our customers. It allows our employees to be confident in the work environment . Genomic Expressions ease of use, turnaround time, support and service has been essential in helping to reduce the risks in continuing our business model "



    We have been featured in Forbes twice, GEN, GenomeWeb and MedWatch. Our investors include Biogen founders, Harvard Business Angels, Investor Circle, Pipeline Angels, and a family office; Centurion Holding in New York.


    We are a Springboard alum company and among the 500 women-owned technology companies they have supported. Genomic Expression came in #2 in the Women’s Founders Pitch event in LA, was in the top 10 companies to pitch for Sir Richard Branson (Virgin Airlines) Extreme Technology Challenge, and was invited to dinner with Branson on Necker’s Island.


    We have brought the company from idea to commercialization for grants, revenue, and angel funding, and are now implementing capabilities to rapidly translate RNA code to novel RNA Theraputics in collaborations with Biotech and Pharma


    This is our founder's story:

  • Articles, Grants, Investors and Customers

    These are our supporters, funders and customers

    broken image


    Genome Danmark

    broken image


    broken image

    Impact Investor

    broken image


    broken image

    Impact Investor

    broken image

    #2 at WFN

    broken image

    Top 10 XTC

    broken image

    Horizon2020 grant

    broken image

    Eurostars Grant

    broken image

    MedTech Innovator Top 50

    broken image

    Winner of the Lyfebulb-Helsinn Award

    broken image

    Winner of the EIC Lifescience Award

    broken image

    Featured in Forbes

    broken image

    Won EUTop50 and invited to present at the European Parliament

    broken image

    Presented at GSTIC addressing the UN sustainability goals in health

    broken image

    Finals of the Blue Cross Blue Shields GuideWell competition for novel COVID19 solutions

    broken image

    In the semi-finals of the XPRIZE for Rapid Covid Testing - $6 million dollar, 6-month competition to develop faster, cheaper, and easier to COVID-19 testing methods at scale.

    broken image

    XPrize Semifinalist Targets 300 Million Tests Per Day With Scalable COVID Self-Test



    The information contained in our website is for general reference only, and should not be relied upon for any medical decision, or as a recommendation for any course of medical treatment. By 'opting-in' to our website, you understand we are not undertaking any responsibility to provide you with medical advice of any kind or character. There is no representation as to the accuracy or completeness of the information on our website, and we have no obligation to update or correct any posted information.


    Follow us on twitter 



    You're awesome. Let's talk.

    broken image
    broken image
    broken image
    broken image
    broken image
    broken image
    broken image
    100 Cummings Center, Suite 451C. Beverly, MA  01915